Dendreon: Medicare Coverage Fears Allayed
Updated with new headline, analyst comments
The meeting announcement was posted Tuesday on the web site of the Centers for Medicare and Medicaid Services (CMS).
"The Centers for Medicare and Medicaid Services (CMS) has called this meeting to consider the currently available evidence regarding the impact of labeled and unlabeled use of autologous cellular immunotherapy treatment on health outcomes of patients with metastatic prostate cancer," the agency's announcement stated.The fact that CMS is focusing its attention on which prostate cancer patients to treat with Provenge and will not consider the broader question of whether or not to reimburse at all for the $93,000-per-treatment drug is a positive and should help allay investor concerns. Deutsche Bank biotech analyst Robyn Karnauskas in a note to clients Tuesday night said she expects CMS will conclude that Provenge coverage should hue closely to the type of prostate cancer patients that were treated in the Provenge clinical trials. That outcome "will not change street estimates in our view," Karnauskas writes, adding, "These eligibility criteria we expect to be put in place are in-line with those of the IMPACT trial. This is the way that we, and the Street, model Provenge's market opportunity." Karnauskas has a buy rating on Dendreon with a $44 price target. Dendreon shares rollercoastered in June when CMS announced that it was opening an assessment to determine a national coverage decision of Provenge, which received FDA approval earlier this year as a treatment for advanced prostate cancer. Since that announcement, Dendreon has indicated that 14 of the 15 regional Medicare carriers are either already reimbursing patients for Provenge or have signaled their intention to do so. Strong demand for Provenge in the form of patients on waiting lists to receive the drug has also been reported by the company. Dendreon shares closed Tuesday up 15 cents to $35.84 but jumped another 66 cents, or almost 2% to $36.50 once investors became aware of the scheduling of the Medicare meeting. --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV